Small & Specialty Drug Branding
Tapping Niche Market Potential
| Publication Date | May 2006 |
|---|---|
| Publisher | Cutting Edge Information |
| Product Type | Report |
| Pages | 191 |
| ISBN Number | not applicable |
| Product Code | CUT00032 |
Summary
Commercializing new drugs continues to challenge companies across the pharmaceutical and biotechnology sectors. Cutting Edge Information published this study to assist individuals and product teams who seek guidance in the allocation of pre- and post-launch marketing resources for small and specialty brands.
The information contained in this report is based on primary research gathered from brand managers and directors, marketing executives and marketing support function team members working with brands marketed in the United States, Europe and worldwide.
The following recommendations and conclusions were among Cutting Edge Information's top study findings:
- Support niche brand launches with stronger promotional infrastructures.
Niche brand development is a catch-22; companies hesitate to invest heavily in a drug targeted for less than $500 million in peak annual sales and niche brands cannot exceed $500 million because they are not properly supported. The highest global spending for any niche brand profiled in this study is...
- Invest more funds in thought leader development than advertising for European launches.
With such limited budgets, brand teams need to be particularly meticulous in allocating resources to the various marketing functions. One core marketing strategy that brand teams approach differently...
- Leverage smaller products for profits and strategic objectives, focusing on brand activities and advertising to grow revenue.
Blockbuster products reach multibillion dollar revenues thanks to their experienced marketing organizations. However, even experienced marketing organizations rely on niche drug launches to fill portfolio gaps and expand into new therapeutic areas. Companies with the promotional wherewithal to maximize niche sales...
- Assign marketing resources in a timely fashion to have greatest impact.
Marketing a niche drug entails great attention to the timing of marketing activities. By the same token, allocating marketing dollars to support these marketing functions during key stage gates in a product's development is paramount to a drug's success...
- Assign global staffing levels according to marketing investment levels and drugs' unique demands.
It is generally true that FTEs increase alongside financial investments. Closer examination of the products, however, shows that dollars spent is not always a predictor of staffing levels...
Content
- Charts and Graphics
- Resource Allocation and Strategic Profiles
- Figure E.1: Study Context: Therapeutic Areas
- Figure E.2: Niche Brand Commercialization Spending Breakdown
- Figure E.3: Percent of Marketing Budget by Phase
- Global Resource Allocation
- Figure 1.1: Niche Brand Global Expenditures and Sales
- Table 1.1: Global Launch Context
- Figure 1.2: Global Spending
- Figure 1.3: Global Staffing
- Figure 1.4: Global Activities Spending
- Figure 1.5: Global Activities Staffing
- Figure 1.6: Global Market Research Spending
- Figure 1.7: Global Market Research Staffing
- Figure 1.8: Global Thought Leader Development Spending
- Figure 1.9: Global Thought Leader Development Staffing
- Figure 1.10: Global Advertising Spending
- Figure 1.11: Global Advertising Staffing
- Brand
- Table 1.2: Brand 1 Spending
- Figure 1.12: Brand 1: Budget Allocation
- Table 1.3: Brand 1 Staffing
- Figure 1.13: Brand 1: Staffing Allocation
- Figure 1.14: Brand 1: Launch Context
- Brand
- Table 1.4 Brand 2 Spending Table
- Figure 1.15: Brand 2: Budget Allocation
- Table 1.5: Brand 2 Staffing Table
- Figure 1.16: Brand 2: Staffing Allocation
- Figure 1.17: Brand 2: Launch Context
- Brand
- Table 1.6: Brand 3 Spending
- Figure 1.18: Brand 3: Budget Allocation
- Table 1.7: Brand 3 Staffing
- Figure 1.19: Brand 3: Staffing Allocation
- Figure 1.20: Brand 3: Launch Context
- Brand
- Table 1.8: Brand 4 Spending
- Figure 1.21: Brand 4: Budget Allocation
- Table 1.9: Brand 4 Staffing
- Figure 1.22: Brand 4: Staffing Allocation
- Figure 1.23: Brand 4: Launch Context
- Brand
- Table 1.10: Brand 5 Staffing
- Figure 1.24: Brand 5: Budget Allocation
- Table 1.11: Brand 5 Spending
- Figure 1.25: Brand 5: Staffing Allocation
- Figure 1.26: Brand 5: Launch Context
- European Marketing
- Figure 2.1: European Marketing Mix
- Table 2.1: European Launch Context
- Figure 2.2: European Total Spending
- Figure 2.3: European Total Staffing
- Figure 2.4: European Brand Activities Spending
- Figure 2.5: European Brand Activities Staffing
- Figure 2.6: European Market Research Spending
- Figure 2.7: European Market Research Staffing
- Figure 2.8: European Thought Leader Development Spending
- Figure 2.9: European Thought Leader Development Staffing
- Figure 2.10: European Advertising Spending
- Figure 2.11: European Advertising Staffing
- Figure 2.12: Average European Marketing Spending as % of European Peak Annual Sales (by Resource Category)
- Figure 2.13: Average Peak European Marketing Staffing (by Resource Category)
- Figure 2.14: European Marketing Spending (as % of European Peak Annual Sales)
- Figure 2.15: Niche Brands' Peak Total Marketing Staffing
- Figure 2.16: Brand Activities Spending (as % of European Peak Annual Sales)
- Figure 2.17: Peak European Brand Activities Staffing
- Figure 2.18: European Market Research Spending (as % of European Peak Annual Sales)
- Figure 2.19: Peak European Market Research Staffing
- Figure 2.20: European Thought Leader Development Spending (as % of European Peak Annual Sales)
- Figure 2.21: Peak European Thought Leader Development Staffing
- Figure 2.22: European Advertising Spending (as % of European Peak Annual Sales)
- Figure 2.23: Peak European Advertising Staffing
- Brand
- Table 2.2: Brand 6 Spending
- Figure 2.24: Brand 6: Budget Allocation
- Table 2.3: Brand 6 Staffing
- Figure 2.25: Brand 6: Staffing Allocation
- Figure 2.26: Brand 6: Launch Context
- Brand
- Table 2.4: Brand 7 Spending
- Figure 2.27: Brand 7: Budget Allocation
- Table 2.5: Brand 7 Staffing
- Figure 2.28: Brand 7: Staffing Allocation
- Figure 2.29: Brand 7: Launch Context
- Brand
- Table 2.6: Brand 8 Spending Table
- Figure 2.30: Brand 8: Budget Allocation
- Table 2.7: Brand 8 Staffing Table
- Figure 2.31: Brand 8: Staffing Allocation
- Figure 2.32: Brand 8: Launch Context
- Brand
- Table 2.8: Brand 9 Spending
- Figure 2.33: Brand 9: Budget Allocation
- Table 2.9: Brand 9 Staffing
- Figure 2.34: Brand 9: Staffing Allocation
- Figure 2.35: Brand 9: Launch Context
- Table 2.10: Brand 10 Spending
- Brand
- Figure 2.36: Brand 10: Budget Allocation
- Figure 2.37: Brand 10: Budget Allocation (Early-Stage)
- Table 2.11: Brand 10 Staffing
- Figure 2.38: Brand 10: Staffing Allocation
- Figure 2.39: Brand 10: Launch Context
- Brand
- Table 2.12: Brand 11 Staffing
- Figure 2.41: Brand 10: Budget Allocation (Early-Stage)
- Figure 2.40: Brand 11: Budget Allocation
- Table 2.13: Brand 11 Spending
- Figure 2.42: Brand 11: Staffing Allocation
- Figure 2.43: Brand 11: Launch Context
- US Commercialization
- Figure 3.1: US Marketing Mix
- Table 3.1: US Launch Context
- Figure 3.2: US Total Spending
- Figure 3.3: US Total Staffing
- Figure 3.4: US Brand Activities Spending
About this Product
Delivery Details
PDF:Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
PRINT/CD-ROM:Despatched within 2 to 4 working days.
Related Products
Recently Viewed Products
- India: Booming Economy sees the Pharmaceutical Market Expand >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Battle for HIV drug market share getting fiercer - maybe too fierce for some >>
- Will Government Support see India’s Tourism Industry Reach $26 billion by 2010? >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















